Skip to main content
Welcome to Health First Inc.
Search Health First Submit Search Criteria    
Health First Now Button

   About Us
   Find a Physician
   Patients & Visitors
   Events & Classes
   News & Media
   Ways to Help
   Careers & Nursing
      Opportunities

   Shop

   My Health First Tools
   For Physicians
   For Clinicians & Staff
   Home

Health First Foundation
Online Scheduling and Pre-Registration
Sign Up for E-bulletins
Normal Text Larger Text

Health First Dermatology Now Offering KYBELLA™, the 1st & Only Injectable Drug for Double Chin

Dr. Anita Saluja among 1st in Brevard to offer new treatment

Anita Saluja, MDROCKLEDGE, Fla. - Health First dermatologist Dr. Anita Saluja is one of the first physicians in Brevard to be trained to offer KYBELLA™ (deoxycholic acid) injection, the first and only FDA-approved injectable drug available that contours and improves the appearance of moderate to severe submental fullness, sometimes referred to as a "double chin."

Submental fullness is a common, yet under-treated aesthetic condition that is often resistant to diet and exercise alone and influenced by several factors, including aging, genetics and weight gain.

"Kybella is the first injectable that we have to treat a double chin and contour the jawline. The best thing is that it is permanent!" said Dr. Saluja, who was recently trained on the proper technique for safely administering the state-of-the-art treatment. "I am excited to bring it to Brevard as a service for our patients. My goal is always to give natural looking results and put safety first."

Each in-office treatment session with KYBELLA™ is typically 15-20 minutes. When injected into subcutaneous fat, KYBELLA™ causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat. After the aesthetic response is achieved with KYBELLA™, re-treatment is not expected. With this nonsurgical treatment, many patients experience visible results in two to four treatment sessions spaced at least one month apart. Up to six treatments may be administered. Treatment with KYBELLA™ is customized by Dr. Saluja to the patient's aesthetic goals for an improved chin profile.

The most common side effects are swelling, bruising, pain, numbness, redness and formation of areas of hardness in the treatment area. In clinical trials, the incidence and severity of most side effects decreased with subsequent KYBELLA™ treatments. KYBELLA™ can cause serious side effects, including trouble swallowing and nerve injury in the jaw that can cause an uneven smile or facial muscle weakness. KYBELLA™ has been the focus of a global clinical development program involving over 20 clinical studies with more than 2,600 patients worldwide, of which 1,600 have been treated with KYBELLA™. To learn more, please visit yourskinourcare.org.

About Health First
Founded in 1995, Health First is Central Florida's only fully integrated delivery network (IDN) and employs more than 8,000 associates. The integrator of its IDN is Health First Health Plans offering a wide variety of health insurance options across Central Florida. In addition, it operates four hospitals (Health First's Cape Canaveral Hospital, Health First's Holmes Regional Medical Center, Health First's Palm Bay Hospital and Health First's Viera Hospital) and is home to Brevard County's only Trauma Center. Health First Medical Group is the largest multi-specialty physician group on the Space Coast. Health First also offers numerous outpatient and wellness services, including Health First Aging Services, four Health First Pro-Health & Fitness Centers and Home and Hospice care. Visit www.health-first.org for more information.

About KYBELLA™
KYBELLA™ is the first and only approved injectable drug for contouring moderate to severe submental fullness, a condition that is commonly referred to as a double chin. KYBELLA™ is a non-human and non-animal formulation of deoxycholic acid, a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat.i When injected into subcutaneous fat, KYBELLA™ causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat.ii KYBELLA™ (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. The safe and effective use of KYBELLA™ for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.